These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1820437)

  • 1. Bone mineral loss in patients on maintenance hemodialysis with hyperphosphatemia treated with 1 alpha-hydroxycholecalciferol and calcium carbonate.
    Nishitani H; Yamakawa M; Nishizawa Y; Morii H
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S113-8. PubMed ID: 1820437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
    Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.
    Laway BA; Goswami R; Singh N; Gupta N; Seith A
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):405-9. PubMed ID: 16584512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy.
    Watson AR; Kooh SW; Tam CS; Reilly BJ; Balfe JW; Vieth R
    Child Nephrol Urol; 1988-1989; 9(4):220-7. PubMed ID: 3255485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in children with chronic renal failure.
    Waller S; Ridout D; Rees L
    Pediatr Nephrol; 2007 Jan; 22(1):121-7. PubMed ID: 16977474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
    Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
    Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 15. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
    Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T; Negi S;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
    Slatopolsky E; Weerts C; Norwood K; Giles K; Fryer P; Finch J; Windus D; Delmez J
    Kidney Int; 1989 Nov; 36(5):897-903. PubMed ID: 2615197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
    Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.